A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety,
tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140
administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects
with advanced solid tumors and lymphoma who have progressed despite having standard therapy
or for which no standard therapy exists.